InterMune's Roch Deal Sends Peer Group Up Monday

InterMune Inc.'s

agreement to be acquired by Roche

for $74 a share sent similar drug development companies up in early trading Monday. InterMune gained 35 percent to $73.08 a share. Infinity Pharmaceuticals Inc.

rose more than 4 percent to $11.42 a share; Gilead Sciences, Inc.

picked up 3 percent to $107.1 a share; Synta Pharmaceuticals Corp.

gained nearly 3 percent to $4.11 a share and Rigel Pharmaceuticals Inc.

gained 2 percent to $2.64. InterMune, which makes a single product for treatment of pulmonary fibrosis approved only in Europe and Canada, had been rumored for sale as early as March. Talk surfaced again earlier this month, with the mention of potential acquirers including Sanofi

, GlaxoSmithKline

and Actelion

. Roche finally inked an $8.3 billion deal Sunday.